Gene Therapy Quality Assurance
and GMP Compliance Consulting
Comprehensive quality assurance for AAV gene therapy and viral vector programs, from QMS design and GMP compliance through adventitious agent testing strategies, vector shedding protocols, and BLA-ready quality systems.
- Patient Safety Is Our North Star
Support Across All Stages Ensuring Compliance and Product Integrity for Gene Therapy
DES Pharma provides comprehensive quality assurance to ensure patient safety across all stages of drug development. Our team confirms that every gene therapy program adheres to regulatory standards, maintains viral vector product integrity, and delivers integrated quality oversight across the entire product lifecycle.
Gene therapy QA requires specialized expertise beyond standard biologic quality systems, including adventitious agent testing programs, vector shedding study design, genotoxicity risk assessments, and CBER-specific inspection readiness strategies that conventional QA frameworks do not address.
Gene Therapy-Specific Compliance Services
Specialized QA capabilities for AAV gene therapy and viral vector regulatory complianceThis includes adventitious agent testing program design (ICH Q5A(R2), 21 CFR 610, USP <71>), vector shedding protocols for clinical and post-marketing studies, and GMP quality system development aligned with CBER expectations for viral vector manufacturing. We bridge the gap between standard biologic QA and the heightened expectations of gene therapy regulation.
Our Quality Approach
Smart, Efficient QA Operations
for Viral Vector Programs
We deliver value through operational efficiency, a streamlined approach to gene therapy quality assurance that prioritizes critical quality activities directly impacting patient safety and robust product supply.
Supplier Management & Qualification
- GMP compliance evaluation of viral vector CDMOs and raw material suppliers
- Quality management system (QMS) design for gene therapy programs
- Vendor qualification for plasmid manufacturers, CDMO, and analytical labs
- Quality agreement (QA) development with risk categorization for AAV supply chain
- Adventitious agent testing laboratory qualification
- Biosafety laboratory qualification and classification support
Auditing & Assessment Systems
- ICH Q9 risk management framework implementation for gene therapy
- Comprehensive GMP audit programs for AAV manufacturing facilities
- Audit finding resolution and CAPA oversight systems
- FDA (CBER) response support and inspection preparation
- Mock FDA Pre-Approval Inspection (PAI) readiness assessments
- EMA GMP inspection readiness support for gene therapy sites
Material Quality Management
- Incoming material inspection and release for viral vector raw materials
- Raw material identification and approval systems (plasmids, resins, media)
- Release documentation management for GMP viral vector components
- Adventitious agent control strategy for raw materials (ICH Q5A(R2))
- Cell substrate qualification and testing program oversight
- Master Cell Bank (MCB) / Working Cell Bank (WCB) release support
Manufacturing Operations QA
- GMP document review, batch record approval for viral vector manufacturing
- Deviation investigation management for gene therapy manufacturing events
- Change control management (manufacturing process, equipment, site)
- Personnel training oversight and GMP qualification programs
- Contamination control strategy development and review
- Environmental monitoring program design for viral vector suites
Supporting Reliable Outcomes
Robust QA Processes Across
All Operations
Technical Operations
CMC documentation review, analytical method lifecycle management, and technical operations qualification
QC Operations
Laboratory document review, deviation and OOS investigation management, and data integrity assessments (21 CFR Part 11)
Product Release
Batch release approval, specification and COA review, Product Quality Review (PQR), and Annual Product Review (APR)
Gene Therapy-Specific
Adventitious agent testing, vector shedding protocols, genotoxicity risk, and CBER-specific compliance oversight
Gene Therapy QA Expertise Specialized Compliance for Viral Vector Programs
Gene therapy quality assurance is categorically distinct from conventional biologic QA. AAV programs face unique compliance requirements: from the design of adventitious agent testing panels aligned with ICH Q5A(R2) to the development of vector shedding study protocols that meet FDA and EMA post-marketing expectations, to the genotoxicity risk frameworks required by CBER.
DES Pharma’s QA consultants have built quality systems specifically for gene therapy programs, understanding the intersection of viral vector biology, manufacturing complexity, and regulatory expectations. We help gene therapy companies build quality cultures and systems that hold up under CBER pre-approval inspections, avoiding the delays that poorly designed gene therapy QA programs consistently produce.
Whether you need to design your first GMP-compliant QMS, prepare for a CBER audit, or develop a vector shedding risk assessment for your clinical program, DES Pharma delivers the specialized quality expertise to keep your gene therapy program compliant and on track.
Adventitious Agent Testing Program Design
ICH Q5A(R2) compliant testing strategy including in-vitro and in-vivo assays, PCR-based screening, and cell-based detection methods for AAV manufacturing
Vector Shedding Protocol Development
FDA- and EMA-aligned shedding study designs for clinical trials and post-marketing commitments: sample collection strategy, assay selection, and data interpretation frameworks
Genotoxicity & Insertional Mutagenesis Risk
Risk-based framework development for integration site analysis, long-term follow-up (LTFU) study design, and regulatory justification for AAV genotoxicity risk assessment
FDA CBER Inspection Readiness
Mock PAI assessments, CBER-specific inspection preparation, prior approval supplement (PAS) strategy, and FDA response support for gene therapy manufacturing
IND / BLA Quality Section Authorship
CMC quality narrative development, quality overall summary (QOS), and CBER-aligned QA section documentation for gene therapy IND and BLA submissions
Key Regulatory Framework
Gene Therapy QA Regulatory
Reference Guide
Critical regulatory requirements that define the compliance framework for AAV gene therapy quality systems, each requiring specialized expertise beyond standard biologic QA.
| Regulatory Requirement | Guideline / Reference | Gene Therapy Significance | Type |
|---|---|---|---|
| Adventitious Agent Testing | ICH Q5A(R2); 21 CFR 610; USP <71> | Mandatory for all viral vector cell substrates and production processes, more extensive than standard biologics | Required |
| Vector Shedding Studies | FDA CBER Guidance 2015; EMA Guideline 2009 | Clinical and post-marketing studies to assess patient-to-patient transmission risk via body fluids | Required |
| Long-Term Follow-Up (LTFU) | FDA CBER Guidance 2020 (GT LTFU) | 15-year patient monitoring program required for integrating gene therapies; AAV risk stratification may reduce duration | Required |
| Genotoxicity / Insertional Risk | FDA 2006 GTGTF; EMA Guideline EMEA/236981 | Risk-based assessment required; AAV generally considered low integration risk but documentation required | GT-Specific |
| Replication Competent Virus (RCV) | FDA CBER Guidance; ICH Q5A | RCV assays required for every AAV lot to confirm absence of replication-competent particles | Required |
| Cell Substrate Qualification | ICH Q5B; ICH Q5D; USP <1010> | MCB/WCB characterization and qualification required for HEK293, Sf9, and other cell substrates used in AAV manufacturing | Required |
| Data Integrity (GMP) | 21 CFR Part 11; FDA DI Guidance 2018; EMA ANNEX 11 | Electronic records and signatures requirements for all GMP data generated during viral vector manufacturing and testing | Required |
Our Quality MethodologyHow We Build Gene Therapy
Quality Systems That Last
A four-step approach to building quality systems that are both compliant and
operationally sustainable for gene therapy programs.
Quality Risk Assessment
Begin with ICH Q9-based risk assessment of your specific gene therapy product, manufacturing platform, and regulatory pathway to identify the highest-priority quality system gaps.
Phase-Appropriate QMS Design
Build quality systems calibrated to your development stage: IND-enabling QA has different requirements than PPQ-stage or BLA commercial quality systems.
Gene Therapy-Specific Protocol Development
Design and execute adventitious agent testing, vector shedding, and genotoxicity risk protocols that meet FDA CBER and EMA expectations for viral vector products.
Inspection Readiness & BLA Support
Prepare for CBER pre-approval inspections, author quality sections for regulatory submissions, and ensure your QA documentation package supports BLA approval.
Get Started
Build a CBER-Ready Gene
Therapy Quality System
Ensure your AAV program meets FDA and EMA compliance
expectations at every stage.